Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATG vs conventional GVHD prophylaxis in HLA 1-locus mismatched unrelated bone marrow transplantation
jRCTs031180435Active, not recruiting
- Sponsor
- The Japanese Society for Transplantation and Cellular Therapy
- Start
- Sep 2017
- Modality
- Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Randomised trial of antithymocyte globulin in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), adult T-cell leukemia-lymphoma (ATLL) and 4 more (2 arms), sponsored by The Japanese Society for Transplantation and Cellular Therapy. Primary endpoint: Success rate at 1 year after transplantation. Started Sep 2017; status: active, not recruiting.
02
Drugs
antithymocyte globulin
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)adult T-cell leukemia-lymphoma (ATLL)chronic myelogenous leukemia (CML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on jRCTs031180435.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180435.